Product Center
2024 National Vaccine and Health Conference
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2024-04-22
- Views:
(Summary description)On April 20-21, the 2024 National Vaccine Conference and Health Conference was held in Xiongan New Area, Hebei Province. Ab&B Bio brought its first product, the quadrivalent influenza virus subunit vaccine (Huierkangxin HRK-X®) to the event again.
2024 National Vaccine and Health Conference
(Summary description)On April 20-21, the 2024 National Vaccine Conference and Health Conference was held in Xiongan New Area, Hebei Province. Ab&B Bio brought its first product, the quadrivalent influenza virus subunit vaccine (Huierkangxin HRK-X®) to the event again.
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2024-04-22 14:06
- Views:
On April 20-21, the 2024 National Vaccine Conference and Health Conference was held in Xiongan New Area, Hebei Province. Ab&B Bio brought its first product, the quadrivalent influenza virus subunit vaccine (Huierkangxin HRK-X®) to the event again.
The theme of this conference is "Standardization & middot; Expansion & middot; Innovation — — Promoting the construction of a healthy China with high-quality immunization services", focusing on the scientific and practical issues involved in the high-quality development of vaccine immunization services. More than 3,000 experts and scholars from medical and health institutions, scientific research institutes, and colleges and universities at all levels across the country attended the meeting on site, and more than 20,000 scientific and technological workers in the field of vaccines and health participated in the meeting online to exchange research results, share practical experience, and discuss optimization strategies.
The booth featuring Ab&B Bio's unique design attracted many experts, teachers, mass media, and industry peers to stop and visit, and they all expressed their attention and expectations for the quadrivalent influenza virus subunit vaccine!
The company's senior leaders visited the booth to interact with experts and teachers, and served people from all walks of life with sincerity and pragmatism!
The marketing department representative enthusiastically and professionally answered questions from people from all walks of life about the quadrivalent influenza virus subunit vaccine! With the help of the on-site influenza virus model, the characteristics of the subunit influenza vaccine that only extracts effective antigens hemagglutinin and neuraminidase are vividly explained.
In the report of the sub-venue "Progress and Application of Vaccine Clinical Trials", Pan Hongxing, director of the Vaccine Clinical Evaluation Institute of Jiangsu Provincial Center for Disease Control and Prevention, took "Progress in Clinical Evaluation of Domestic New Influenza Vaccines" as the theme, and introduced the relevant progress of the domestic new quadrivalent subunit influenza vaccine from the aspects of the current status of influenza vaccine application in China and the world, the phased safety data of the Phase III clinical study of the domestic new quadrivalent subunit influenza vaccine and the scientific research project of the National Evaluation Center.
Since its establishment in 2005, Bio has been committed to the research, development, production and sales of innovative vaccines for human use. The HRK-X®, which has been launched on the market, is the first quadrivalent subunit influenza vaccine in China and is registered as a new class I biological product for preventive use. Ab&B Bio actively supports the development of vaccine immunization and the construction of a healthy China in my country, and actively supports influenza prevention and control, so that more people can be vaccinated with safer and more efficient influenza vaccines.
Relevant information
-
Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvantsOn August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd, a wholly-owned subsidiary of Ab&B Bio Tech Co., Ltd (locally referred to as "Zhonghui Bio"), made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal "Journal of Drug Delivery Science and Technology" under the title "Dual functional Emulsifier Based Nano Emulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice". - Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
- IND application for quadrivalent influenza virus subunit vaccine (adjuvant) approved 07-30
- World Influenza Conference 2024 | Decoding new possibilities for the future of influenza vaccines 07-09
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
